Table 2.

Factors associated with overall and progression‐free survival, multivariable model

Variable	Risk of death			Risk of progression
	HR (95% CI)	Standard error	χ2	HR (95% CI)	Standard error	χ2
sPBC vs. sNPBC	0.72 (0.53–0.98)	0.16	0.035	0.83 (0.64–1.08)	0.13	0.159
ECOG PS
1 vs. 0	1.52 (0.99–2.33)	0.22	0.055	0.99 (0.73–1.34)	0.16	0.931
≥2 vs. 0	2.02 (1.21–3.37)	0.26	0.007	1.57 (1.01–2.44)	0.23	0.048
Unknown vs. 0	1.87 (1.16–2.96)	0.24	0.010	1.15 (0.81–1.64)	0.18	0.423
CCI
1 vs. 0	1.04 (0.59–1.83)	0.29	0.904	1.31 (0.86–1.99)	0.22	0.216
2 vs. 0	0.79 (0.52–1.19)	0.21	0.259	0.87 (0.61–1.25)	0.18	0.458
≥3 vs. 0	1.16 (0.80–1.67)	0.19	0.437	1.11 (0.81–1.53)	0.16	0.511
Liver metastases
Yes vs. no	1.39 (1.00–1.93)	0.17	0.053	1.19 (0.90–1.59)	0.15	0.229
Unknown vs. no	1.45 (0.57–3.70)	0.48	0.434	0.56 (0.16–2.03)	0.66	0.378
Number of fPBC cycles	1.07 (0.96–1.19)	0.06	0.217	1.15 (1.04–1.27)	0.05	0.007
Best response to fPBC
PR vs. CR	0.83 (0.45–1.19)	0.32	0.565	1.21 (0.73–1.99)	0.26	0.467
SD vs. CR	0.92 (0.48–1.55)	0.33	0.806	1.47 (0.87–2.49)	0.27	0.149
PD vs. CR	1.02 (0.52–1.77)	0.34	0.946	1.76 (0.98–3.19)	0.30	0.060
Unknown vs. CR	0.84 (0.37–2.00)	0.41	0.676	1.64 (0.90–3.01)	0.31	0.108
Months elapsed since fPBC	0.99 (0.96–1.01)	0.01	0.270	0.98 (0.97–1.00)	0.01	0.082

Abbreviations: CI, confidence interval; CCI, Charlson Comorbidity Index; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; fPBC, first‐line platinum‐based chemotherapy; HR, hazard ratio; PD, progressive disease; PR, partial response; SD, stable disease; sNPBC, subsequent non–platinum‐based chemotherapy; sPBC, subsequent platinum‐based chemotherapy.